MARIETTA, Ga., Oct. 18, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that MiMedx is the Grand Sponsor of Desert Foot 2016, The Annual High Risk Diabetic Foot Conference Honoring Our Federal Services Healthcare Professionals. Held in Phoenix, Arizona, the 2016 Desert Foot Conference begins October 19, 2016, and concludes on October 22, 2016.
Parker H. "Pete" Petit, CEO, said, "We are honored to be the Grand Sponsor of Desert Foot 2016. The Conference is an educational program designed to enable participants to improve clinical care for patients with diabetes and non-diabetes related lower extremity pathologies who present to physicians and clinicians of multiple specialties. Our full line of products will be discussed in a symposium, a number of podium presentations, in-both education, and workshops. In addition, there are also a number of Continuing Medical Education ("CME") programs during the conference that discuss dHACM and umbilical cord products."
Seven poster abstracts will be presented at Desert Foot 2016 that report on the clinical and cost effective healing results of the MiMedx's EpiFix and AmnioFix dehydrated Human Amnion/Chorion Membrane (dHACM) allografts and the EpiCord dehydrated human umbilical cord allografts in surgical applications and healing of diabetic foot ulcers, chronic diabetic lower extremity ulcerated wounds, venous leg ulcers, complex wounds, and hard-to-treat wounds.
MiMedx will sponsor a symposium entitled "Clinical Efficacy of EpiFix and AmnioFix dehydrated human amnion/ chorion membrane allografts in Surgical and Wound Care Applications" on Wednesday, October 19th in the Phoenix Ballroom main lecture hall. The symposium faculty and presenters include Matthew Garoufalis, DPM, and Thomas Koob, PhD, MiMedx Chief Scientific Officer.
MiMedx will sponsor three workshops on its products during the conference. The first workshop, "Application Techniques and Therapeutic Approaches Using EpiFix, EpiCord & AmnioFix Allografts for Wound Healing and Surgical Procedures", will be presented by Matthew Garoufalis, DPM, Brandon Hawkins, DPM, Myron Hansen, DPM, Tom Koob, PhD, and Michelle Massee, Manager of Biomedical Research at MiMedx, on Wednesday, October 19th. The workshop, "Application Techniques and Therapeutic Approaches Using EpiFix & AmnioFix Allografts for Wound Healing, Surgical & Ultrasound-assisted Procedures", will be presented by David Bernstein, DPM, Richard Terebessey, DPM, and Tom Koob, PhD, on Thursday, October 20th.
The final workshop, "Wound and Integumentary Post-Surgical Complications of the Diabetic Limb", will be presented on Saturday, October 22nd, as part of the Indian Health Service ("IHS") Limb Preservation Summit that immediately follows the Desert Foot Conference. Alberto Abrebaya, DPM, will present this workshop.
The abstracts chronicling independent case studies and respective conclusions undertaken by the presenters relative to MiMedx allografts include:
- Abstract: "Atypical Foot Wounds Treated with Dehydrated Human Amnion/Chorion Membrane Mesh Allografts"
Author: Brandon Hawkins, DPM.
- Abstract: "Use of Amnion Chorion Dehydrated Human Membrane in the Valenti Procedure for Hallux Limitus: A Case Series"
Authors: Mike Czurylo, DPM; Aamir Mahmood, DPM; Laith Shaman, DPM; Patrick Sanchez, DPM; Jake Ruff, DPM; Sarah Park, DPM; Justin Goldsmith, DPM; Andrea Seat, DPM; Anna Tien, DPM; Matthew Garoufalis, DPM.
- Abstract: "Highlighting Various Application Methods of dHACM for Wound Healing in a Compromised Urban Veteran Population"
Authors: Laith Shaman, DPM; Aamir Mahmood, DPM; Mike Czurylo, DPM; Patrick Sanchez, DPM; Jake Ruff, DPM; Sarah Park, DPM; Justin Goldsmith, DPM; Andrea Seat, DPM; Anna Tien, DPM; Matthew Garoufalis, DPM.
- Abstract: "The Use of Dehydrated Umbilical Cord in the Successful Treatment of Chronic Wounds"
Author: Matthew Garoufalis, DPM.
- Abstract: "The Use of Injectable Micronized Amnion/Chorion Membrane in the Successful Treatment of Chronic Wounds"
Author: Matthew Garoufalis, DPM.
- Abstract: "Wound and Integumentary Postsurgical Complications of the Diabetic Limb"
Authors: Keith Goss, DPM; Alberto Abrebaya, DPM.
- Abstract: "Healing of Chronic Lower Extremity Wounds Utilizing a 4-Week Assessment of Healing to Initiate Treatment with Appropriate Sized dHACM and Subsequently Achieve Healing in a Veteran Patient Population"
Authors: Anna Tien, DPM; Michael Czurylo, DPM; Laith Shaman, DPM; Jake Ruff, DPM; Aamir Mahmood, DPM; Patrick Sanchez, DPM; Sarah Park, DPM; Andrea Seat, DPM; Justin Goldsmith, DPM; Matthew Garoufalis, DPM.
Bill Taylor, President and COO, said, "The Desert Foot 2016 Conference provides an ideal forum for top national speakers and Key Opinion Leaders ("KOLs") to convey state-of-the-art training, therapeutic practice and application updates as well as clinical study conclusions on skin, nail disorders, advanced wound care, surgical procedures, and new techniques in the management of diabetic and non-diabetic foot disorders. We are proud of our association with Desert Foot."
MiMedx will be exhibiting in booth # 20-21 during all booth times throughout the four day meeting.
EpiFix is a human amniotic allograft tissue uniquely processed through the Company's proprietary PURION® Process. EpiFix modulates inflammation, reduces scar tissue formation and enhances healing. With a variety of sizes available, EpiFix minimizes graft waste. EpiFix is a minimally manipulated, dehydrated non-viable cellular amniotic membrane allograft that preserves and delivers multiple extracellular matrix proteins, growth factors, cytokines and other specialty proteins present in amniotic tissue. The Company's PURION Process combines cleaning, dehydration and terminal sterilization, making EpiFix a safe and easy to use allograft stored at ambient conditions for up to 5 years.
AmnioFix is a composite amniotic tissue membrane minimally manipulated to protect the collagen matrix and its natural properties. AmnioFix reduces scar tissue formation, modulates inflammation in the surgical site, enhances healing and acts as a barrier membrane. AmnioFix is processed through the proprietary PURION Process that combines cleaning, dehydration and terminal sterilization, making AmnioFix a safe and easy to use allograft stored at ambient conditions for up to 5 years. The proprietary PURION Process protects the delicate scaffold during processing, leaving an intact collagen matrix. The result is a durable graft with natural barrier properties to optimize surgical performance.
EpiCord is a unique, thick membrane derived from umbilical cord, the structure that protects the arteries and vein that carry essential nourishment and oxygenated blood to and from mother and fetus. EpiCord is a minimally manipulated, dehydrated, non-viable cellular umbilical cord allograft for homologous use. EpiCord provides a protective environment for the healing process, and provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue. EpiCord is processed using the PURION PLUS Process, a unique approach that provides an easy to use allograft stored at ambient conditions.
AmnioFill is the first product in the MiMedx placental collagen matrix product family to be commercially launched. AmnioFill is designed to treat larger acute and chronic wounds encountered in the surgical setting. AmnioFill is being offered in multiple sizes to address this and other surgical needs. AmnioFill is a collagenous matrix derived from the placenta and comprised of placental extracellular matrix (ECM) tissue. AmnioFill is a tissue allograft containing ECM proteins, growth factors, cytokines and other specialty proteins present in placental tissue. Over 226 growth factors, cytokines and chemokines, including important modulators of inflammation and factors critically important in wound healing, are contained in the AmnioFill placental tissue.
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix, EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Certain of the risks and uncertainties that could cause actual results to differ materially from such forward-looking statements include the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2015 and its most recent 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-is-grand-sponsor-of-desert-foot-2016-300346683.html
SOURCE MiMedx Group, Inc.